

- 54 Akuta N, Suzuki F, Hirakawa M *et al.* Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. *J Med Virol* 2010; 82: 575–82.
- 55 Izopet J, Payen JL, Alric L *et al.* Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. *J Med Virol* 1998; 54: 86–91.
- 56 Poynard T, Marcellin P, Lee SS *et al.* Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998; 31: 1426–32.
- 57 Izumi N, Enomoto N, Uchihara M *et al.* Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. *Dig Dis Sci* 1996; 41: 989–94.
- 58 Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. *Trends Endocrinol Metab* 2010; 21: 33–40.

Original Article

α -Galactosylceramide activates antitumor immunity against liver tumor

Tomohide Tatsumi,¹ Tetsuo Takehara,¹ Takuya Miyagi,¹ Tsukasa Sugiyama,¹ Hiroshi Aketa,¹ Akira Sasakawa,¹ Tatsuya Kanto,¹ Naoki Hiramatsu¹ and Norio Hayashi^{1,2}

¹Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka and ²Kansai-Rosai Hospital, Amagasaki, Hyogo, Japan

Aim: α -Galactosylceramide (α -GalCer) has been attracting attention as a novel approach to treat metastatic liver cancer. We investigated the detailed process of activating liver dendritic cells (DC) and immune cells after α -GalCer treatment in the mouse liver tumor model.

Methods: BALB/c mice bearing CMS4 liver tumor (p53 peptide-expressing tumor) were treated by α -GalCer. We evaluated the activation of liver DC and immune cells after α -GalCer treatment. Interferon (IFN)- γ enzyme-linked immunosorbent spot (ELISPOT) assay was performed to detect p53 peptide-specific cytotoxic T lymphocytes (CTL). To assess the impact of systemic acquired immunity by α -GalCer treatment, 28 days after liver tumor treatment, CMS4 cells or Colon26 cells were re-challenged s.c.

Results: The liver weights of α -GalCer-treated mice were significantly lighter than those of vehicle-treated mice. Depletion experiments revealed that natural killer (NK) cells were essential for the antitumor effect of α -GalCer. α -GalCer treatment

significantly increased the population of DC and NK cells in the liver. The expressions of co-stimulatory molecules on liver DC significantly increased with the peak at 1 day after α -GalCer administration. IFN- γ ELISPOT assay demonstrated that p53 peptide-specific CTL was generated efficiently in α -GalCer-treated mice. ⁵¹Cr-release assay revealed that CD8⁺, not CD4⁺, CTL against CMS4 cells were generated in α -GalCer-treated mice. The mice that had been protected from CMS4 liver tumor by α -GalCer injection became resistant against s.c. CMS4 re-challenge, but not against Colon26 re-challenge.

Conclusion: These results demonstrated the therapeutic potential of α -GalCer against liver cancer through activating liver DC and immune cells in the liver.

Key words: α -galactosylceramide, cytotoxic T lymphocytes, dendritic cells, liver, natural killer cells.

INTRODUCTION

THE GLYCOLIPID ANTIGEN α -galactosylceramide (α -GalCer) induced the activation of natural killer (NK) T cells in a CD1d-dependent manner.^{1,2} Recently, α -GalCer has been attracting attention as a novel antitumor therapy. In *in vivo* animal studies, systemic administration of α -GalCer showed antitumor effects against various tumors (including melanoma, sarcoma, colon carcinoma and lymphoma) in hepatic and lung

metastasis models.^{3,4} Based on the promising results of preclinical studies demonstrating the antitumor potential of α -GalCer, several phase 1 clinical studies on cancer immunotherapy by the i.v. administration of α -GalCer has been carried out, but clinical responses of α -GalCer has been limited.⁵ No clinical trial against liver cancer has been reported to date. In view of future α -GalCer treatment of liver cancer, the precise mechanism of activation of innate and acquired immunity in the liver by α -GalCer should be examined. However, these are still not fully understood.

The liver contains both a large compartment of innate immune cells (NK cells and NKT cells) and acquired immune cells (T cells).^{6,7} Dendritic cells (DC) can induce the generation of both antigen-specific cytotoxic T lymphocytes (CTL) and T-helper (Th) cells.^{8,9} Recent research of DC biology revealed that DC also contribute

Correspondence: Dr Tomohide Tatsumi, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Email: tatsumit@gh.med.osaka-u.ac.jp
Received 23 July 2010; revision 8 October 2010; accepted 18 October 2010.

to innate immune responses by activating NK cells^{10–14} and NKT cells^{1,15,16} through interleukin (IL)-12 secretion and direct cellular interaction. Thus, DC can be expected to play critical roles in activating abundant T cells, NK cells and NKT cells in the liver after α -GalCer administration. We previously reported that administration of α -GalCer stimulated hepatic NKT cells and led to activation of hepatic NK cells,⁴ and that α -GalCer activated liver DC have higher ability to generate acquired immunity.¹⁷ However, the detailed process of activating liver DC and immune cells after α -GalCer treatment should be elucidated.

In this study, we evaluated the liver DC activation and antitumor effect mediated by both innate and acquired immunity against mouse liver tumor after administration of α -GalCer. Administration of α -GalCer induced early activation of liver DC with upregulation of antigen presenting-related molecules and resulted in complete rejection of local liver tumor by NK cells. Followed by early rejection of liver tumor, tumor antigen-specific CTL were generated and complete rejection in s.c. re-challenge of tumor cells was observed. Sequential activation of liver DC, innate and acquired immune cells in the liver may be an attractive strategy for treatment of local and distant tumor of liver cancer.

METHODS

Mice

SIX-TO-EIGHT-WEEK-OLD female BALB/c mice were purchased from Shizuoka Experimental Animal Laboratory (Shizuoka, Japan). All mice were maintained in micro-isolator cages. Procedures were performed according to approved protocol and in accordance with recommendations for the proper care and use of laboratory animals.

Cell lines and culture

CMS4 sarcomas (H-2^d) express mutated p53 and present the wild-type p53_{232–240} epitope recognized by H-2K^d-restricted CTL.¹⁸ Colon26, a mouse colon adenocarcinoma cell line, was kindly provided by Dr Takashi Tsuruo (Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan). These cell lines were maintained as previously described.^{19,20}

α -GalCer

α -Galactosylceramide was purchased from Funakoshi (Tokyo, Japan) and prepared as previously described by Kawano *et al.*¹

Animal experiments

BALB/c mice were injected in the liver with 5×10^5 CMS4 cells on day 0. On day 1, BALB/c mice were injected i.p. with α -GalCer (2 μ g/100 μ L) or 100 μ L of vehicle. Two weeks after the tumor injection, the livers of treated mice were removed, and the weight was measured to examine intrahepatic tumor growth. To assess the impact of systemic immunity from i.p. injection of α -GalCer, mice were injected intrahepatically with 5×10^5 CMS4 cells on day 0 and i.p. treated with α -GalCer on day 1. On day 28 after α -GalCer treatment, 1×10^6 CMS4 cells or Colon26 cells were injected in the right flank of treated mice. To confirm the involvement of CD8⁺ T cells in this antitumor effect, we depleted CD8⁺ T cells before re-challenge of CMS4 cells in α -GalCer-treated mice. On day 1 and day 3 of re-challenge of CMS4 cells, anti-CD8 antibody (53–6.72 hybridoma, ATCC) was injected i.p. as previously described.¹⁹ Tumor size was assessed every 3 or 4 days and recorded in mm² by determining the product of the largest perpendicular diameters measured by vernier calipers. Data are reported as the average tumor area \pm standard deviation (SD).

NK cell depletion experiments

For NK cell depletion, mice were injected with anti-asialo GM-1 (ASGM1) antibody (Ab) (Wako, Osaka, Japan) on day 1, 5, 10, 15 and 20 after tumor inoculation. The efficiency of NK cell depletion was validated by flow cytometry analysis of splenocytes using phycoerythrin (PE)-conjugated anti-DX5 monoclonal antibody (BD-Pharmingen, San Diego, CA, USA). In all cases, 99% of the targeted cell subset was specifically depleted (data not shown).

Preparation of hepatic mononuclear cells and liver DC

Hepatic mononuclear cells (MNC) were prepared as previously described.⁴ CD11c⁺ dendritic cells were isolated from hepatic MNC by magnetic cell sorting using MACS (Miltenyi Biotec, Gladbach, Germany) according to the manufacturer's protocol.

Flow cytometry

For phenotypic analysis of liver DC, NK cells, NKT cells and CD4⁺ and CD8⁺ T cells, PE- or fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies against mouse cell surface molecules (CD11c, CD40, CD80, CD86, T-cell receptor [TCR]- β , CD49b [DX5], CD4, CD8, CD69 [all from BD-Pharmingen], major his-

to compatibility complex [MHC] class II [Miltenyi Biotec]), and appropriate isotype controls were used, and flow cytometric analysis was performed using a FACScan (Becton Dickinson, San Jose, CA, USA) flow cytometer. The results of flow cytometric analysis are reported in positive cell rates (%) determined by using isotype controls. DC were identified as CD11c⁺/MHC class II⁺ cells. NK cells were identified as DX5⁺/TCR-β⁻ cells, NKT cells as DX5⁺/TCR-β⁺ cells, as previously described.²⁰

IFN-γ enzyme-linked immunosorbent spot (ELISPOT) assays for p53₂₃₂₋₂₄₀ peptide-reactive CD8⁺ T-cell responses

Bone marrow derived DC (BMDC) were generated from normal mice as previously described²¹ and were used as peptide-presenting cells. On day 14 after treatment of α-GalCer or vehicle, CD8⁺ T cells were isolated from the spleen cells of treated mice by using magnetic beads (Miltenyi Biotec). We used a mouse IFN-γ ELISPOT kit (R&D systems, Minneapolis, MN, USA) to detect the p53₂₃₂₋₂₄₀ peptide-specific CD8⁺ T-cell responses. To evaluate the p53₂₃₂₋₂₄₀ peptide, strongly expressing on CMS4 cells,¹⁸ specific CTL induction, isolated CD8⁺ T cells (1 × 10⁵ cells/well) were co-cultured with syngeneic BMDC (2 × 10⁴ cells/well) pulsed with p53₂₃₂₋₂₄₀ peptide in an ELISPOT culture plate. BMDC cells without p53₂₃₂₋₂₄₀ peptide served as the negative control, and this value was subtracted from all experimental determinations to establish p53₂₃₂₋₂₄₀ peptide-specific spot numbers. The data are represented as mean IFN-γ spots ± SD per 100 000 CD8⁺ T cells analyzed.

Cytolytic assays

Splenocytes from α-GalCer or vehicle-treated mice were harvested 14 days after tumor inoculation. After 5 days of *in vitro* stimulation with mitomycin-C (Kyowa Hakko, Tokyo, Japan)-treated CMS4 cells, lymphocytes were analyzed for their ability to kill CMS4 cells in 4-h ⁵¹Cr-release assays (effector cells/target cells ratio, 60:1), as previously described.²¹ CD4⁺ or CD8⁺ T cells were depleted by magnetic sorting using CD4 or CD8 microbeads (Miltenyi Biotec), respectively.

Statistical analyses

All experiments with three or more groups in which treatment was applied with a completely random design were first analyzed by a one-way factorial ANOVA. If the resulting *P*-value was less than 0.05, specific pairwise




Figure 1 Therapeutic effectiveness of i.p. injection of α-galactosylceramide (α-GalCer) in CMS4 liver tumor model. BALB/c mice were injected into-hepatically with 5 × 10⁵ CMS4 cells. One day later, BALB/c mice were treated with i.p. injection of α-GalCer or vehicle (all treatment groups, n = 7). Two weeks after the CMS4 tumor injection, the livers of treated mice were removed. (a) Representative liver macroscopic view of each group. (b) Comparison of liver weight of each group. **P* < 0.05. (c) To prove that the therapeutic benefit of α-GalCer treatment in the CMS4 liver tumor model is natural killer (NK)-cell dependent, *in vivo* depletion of NK cells was performed (as described in Methods, ASGM1). In control mice, isotype antibody (Ab) was injected i.p. (isotype). Both mice were treated by α-GalCer. Ab-mediated *in situ* depletion of NK cells markedly reduces the therapeutic efficacy of α-GalCer treatment (all treatment groups n = 5). **P* < 0.05.




Figure 2 α -Galactosylceramide (α -GalCer) treatment increased dendritic cell (DC) population in the liver mononuclear cells (MNC) and activated DC functions. (a) BALB/c mice were treated with α -GalCer or vehicle. Hepatic MNC were prepared on days 0, 0.5, 1, 3 and 7. DC (CD11c⁺ major histocompatibility complex [MHC] class II⁺ cells) population was evaluated by flow cytometry. White bar, vehicle-treated mice; black bar, α -GalCer-treated mice. Representative dot plots of liver DC (CD11c⁺ MHC class II⁺ cells) at day 1 after α -GalCer or vehicle administration are shown in the left panels. The calculated percentages of liver DC are shown in the right. (b) BALB/c mice were treated with α -GalCer or vehicle. Hepatic MNC were prepared on day 0, 1, 3 and 7 and DC were isolated from liver MNC by a magnetic cell sorting system. For phenotypic analysis, liver DC were stained with phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (CD11c, CD40, CD80, CD86), and the expressions of these molecules were analyzed by flow cytometry. White bar, vehicle-treated mice; black bar, α -GalCer-treated mice. * $P < 0.05$ vs vehicle-treated mice, # $P < 0.05$ vs non-treated mice. Representative histograms of the expressions of CD80, CD86 and CD40 on liver DC at day 1 after α -GalCer or vehicle administration are shown in the upper panels.

contrasts were tested with a Student's *t*-test with Welch's correction for unequal variance as needed.

RESULTS

α -GalCer administration inhibited CMS4 liver tumor mediated by NK cells

WE INITIALLY EXAMINED whether α -GalCer administration could induce antitumor effect against CMS4 liver tumor. As shown in Figure 1(a), no tumors were observed in the livers of α -GalCer-treated mice whereas large tumors were observed in the livers of vehicle-treated mice. The liver weight of the α -GalCer treatment group was significantly lighter than that of the vehicle treatment group (Fig. 1b). Depletion of NK cells significantly inhibited the antitumor efficacy of α -GalCer treatment (Fig. 1c), whereas depletion of neither CD4⁺ nor CD8⁺ T cells was inhibited (data not shown). These results suggested that administration of α -GalCer was therapeutic against CMS4 liver tumor and NK cells were the main effector cells in this antitumor immunity.

Administration of α -GalCer increased DC population in the liver MNC and activated DC functions

We investigated the population changes of DC in the liver MNC after α -GalCer or vehicle treatment. On day 1 after α -GalCer administration, liver DC proportion in α -GalCer-treated mice was higher than that in vehicle-treated mice (Fig. 2a). Liver DC proportion increased with the peak at 1 day after α -GalCer administration and the liver DC proportion at 7 days decreased to the same level with that from non-treated mice (Fig. 2a). In contrast, liver DC proportion in vehicle-treated mice exhibited weaker change than those in α -GalCer-treated mice (Fig. 2a). The liver DC number also exhibited increase at the peak of 1 day after α -GalCer administration whereas that from vehicle-treated mice exhibited no change (data not shown). We examined the CD40, CD80 and CD86 expressions of liver DC after administration of α -GalCer, which is an indicator of DC activation. On

day 1 after α -GalCer administration, CD40, CD80 and CD86 on liver DC from α -GalCer-treated mice expressed more strongly than those from vehicle-treated mice (Fig. 2b). The expressions of all these molecules on liver DC increased with the peak at 1 day after α -GalCer administration and the expression levels of these molecules at 7 days decreased to the same levels on liver DC from non-treated mice (Fig. 2b). In contrast, the expressions of these molecules on liver DC exhibited weaker change in vehicle-treated mice.

Activated NK cells composed the major subpopulation of hepatic MNC that increased after α -GalCer treatment


We examined the population change of MNC from the livers after α -GalCer or vehicle administration. It is notable that NK cells strikingly increased in proportion after α -GalCer administration, but not after vehicle administration (Fig. 3a). In contrast, the NKT cells decreased at 1 and 3 days after α -GalCer administration and recovered at day 7 after α -GalCer administration. Both CD4⁺ and CD8⁺ T cells decreased in proportion after α -GalCer administration, but not after vehicle administration. We also examined the CD69 expressions of NK cells, which is an indicator of lymphocyte activation. The CD69 expressions on liver NK cells increased with the peak at 1 day and gradually decreased at 7 days after α -GalCer administration (Fig. 3b). In contrast, those did not change after vehicle administration. These results demonstrated that the activated NK cells were the major subpopulation of MNC that increased in the liver after α -GalCer administration.

p53₂₃₂₋₂₄₀ peptide-specific CTL were generated after α -GalCer treatment of liver tumor


We evaluated whether p53₂₃₂₋₂₄₀ peptide-specific CTL were generated after α -GalCer treatment of liver tumor. CD8⁺ T cells were isolated from the spleen cells of treated mice and then co-cultured with syngeneic DC pulsed with p53₂₃₂₋₂₄₀ peptide strongly expressed on CMS4 cells. As shown in Figure 4(a), the number of

Figure 3 Activated natural killer (NK) cells composed the major subpopulation of hepatic mononuclear cells (MNC) that increased after α -galactosylceramide (α -GalCer) treatment. (a) BALB/c mice were treated with α -GalCer or vehicle. Hepatic MNC were prepared on days 0, 1, 3 and 7. NK cells, NKT cells, CD4⁺ T cells and CD8⁺ T cells in liver MNC were evaluated by flow cytometry. (b) The expressions of CD69 on liver NK cells were also evaluated by flow cytometry. White bar, vehicle-treated mice; black bar, α -GalCer-treated mice. **P* < 0.05 vs vehicle-treated mice.

(a)



(b)






Figure 4 Evaluation of p53₂₃₂₋₂₄₀ peptide-specific CD8⁺ cytotoxic T lymphocytes (CTL) in α-galactosylceramide (α-GalCer)-treated mice. (a) CD8⁺ T cells were isolated from the spleen cells of treated mice 14 days after α-GalCer or vehicle treatment. The frequency of p53₂₃₂₋₂₄₀ peptide-specific CD8⁺ CTL was evaluated by interferon (IFN)-γ enzyme-linked immunosorbent spot (ELISPOT) assay. The results are shown in spots/100 000 CD8⁺ T cells; mean ± standard deviation of triplicate samples. **P* < 0.05. (b) Splenocytes from α-GalCer- or vehicle-treated mice were harvested 14 days after tumor inoculation and were analyzed for their ability to kill CMS4 cells in 4 h ⁵¹Cr-release assays (effector cells/target cells ratio, 60:1). CD4⁺ or CD8⁺ T cells were depleted by magnetic sorting using CD4 or CD8 microbeads (Miltenyi Biotec), respectively. CD8⁻, CD8⁺ T-cell-depleted splenocytes. CD4⁻, CD4⁺ T-cell-depleted splenocytes. **P* < 0.05 vs the cytolytic activity of splenocytes from α-GalCer-treated mice.

IFN-γ spots (per 100 000 CD8⁺ T cells) observed for T-cell responses against p53₂₃₂₋₂₄₀ peptide in α-GalCer-treated mice were significantly higher than that in vehicle-treated mice. These results suggested that strong p53₂₃₂₋₂₄₀ peptide-specific CTL were generated by α-GalCer treatment of liver tumor. Splenocytes from α-GalCer-treated mice displayed strong cytolytic activity against CMS4 cells, while those from vehicle-treated mice did not (Fig. 4b). CD8⁺ T-cell-depleted splenocytes from α-GalCer-treated mice displayed significant weak cytolytic activity against CMS4 cells, but CD4⁺ T-cell-depleted splenocytes did not. These results demonstrated that CD8⁺ T cells (i.e. CTL) played essential roles in the cytolytic activity against CMS4 cells in α-GalCer-treated mice.

Systemic therapeutic antitumor immunity was induced by α-GalCer treatment of CMS4 liver tumor

Because strong p53₂₃₂₋₂₄₀ peptide-specific CTL were generated in α-GalCer-treated animals, we next chose to analyze whether the treatment of a CMS4 lesion in the liver would impact the progression of subcutaneous untreated CMS4 tumors. BALB/c mice were intrahepatically injected with CMS4 tumors and treated by administration of α-GalCer. Twenty-eight days later, 1 × 10⁶ CMS4 cells or Colon26 cells were injected s.c. in the right flank. As shown in Figure 5(a), the non-treated CMS4 tumors in mice receiving α-GalCer treatment were completely rejected in all mice. The growth of non-treated Colon26 tumor in α-GalCer-treated mice was not inhibited (Fig. 5b). These results suggested that systemic CMS4-specific antitumor immunity could be induced by α-GalCer treatment. To confirm the involvement of CTL in this antitumor effect, we depleted CD8⁺ T cells before re-challenge of CMS4 cells (s.c. injection of 1 × 10⁶ CMS4 cells) in α-GalCer-treated mice bearing CMS4 liver tumor. On days 1 and 3 of re-challenge of CMS4 cells, anti-CD8 antibody (53-6.72 hybridoma, ATCC) was injected i.p. As shown in Figure 5(c), antitumor effect against re-challenged CMS4 subcutaneous tumor was diminished in CD8⁺ T-cell-depleted mice. These results supported that CD8⁺ T cells (i.e. CTL) play essential roles in the antitumor effect against re-challenge of CMS4 cells in α-GalCer-treated mice.

DISCUSSION

WE PREVIOUSLY DEMONSTRATED that administration of α-GalCer activated both NKT cells and NK cells in the liver, and that liver NK cells were the




Figure 5 α -Galactosylceramide (α -GalCer) therapy results in the development of systemic antitumor immunity that protects distal tumor re-challenge. BALB/c mice were injected intrahepatically with CMS4 tumors. Twenty-four hours later, the mice were treated with α -GalCer. Twenty-eight days after treatment, α -GalCer-treated mice were re-challenged s.c. with 1×10^6 CMS4 cells (a) or Colon26 cells (b) in the right flank (all treatment groups, $n = 8$). To confirm the involvement of cytotoxic T lymphocytes (CTL) in this antitumor effect, we depleted CD8⁺ T cells before re-challenge of CMS4 cells in α -GalCer-treated mice bearing CMS4 liver tumor (c). On days 1 and 3 of re-challenge of CMS4 cells, anti-CD8 antibody was injected i.p. Tumor size was assessed every 3 or 4 days after s.c. injection of tumor cells (on day 0). As control mice, naïve mice were injected s.c. with 1×10^6 CMS4 cells (a, $n = 8$; c, $n = 6$) or Colon26 cells (b) ($n = 8$) on day 0. (●) α -GalCer-treated mice, (▲) control mice. Each data point represents the mean tumor size \pm standard deviations.

main effector cells to kill disseminated hepatoma cells injected from spleen in α -GalCer treatment.⁴ In this study, we evaluated α -GalCer treatment in local injected liver tumor, and the α -GalCer treatment resulted in complete rejection of local liver tumor, which had a similar antitumor effect as α -GalCer in a previous metastatic liver tumor model. These findings suggested the ability of α -GalCer treatment to activate the liver NK cells efficiently, which may mainly contribute to eradication of local liver tumor cells. A normal liver contains lymphocytes that are usually enriched with NK and NKT cells; namely, 25% NK cells and 30% NKT cells in contrast to peripheral blood that contains only 10% NK and 5% NKT cells.^{6,7} Thus, activation of innate immune cells, NK cells and NKT cells must be important to develop more effective immunotherapy against liver cancer. We believe that α -GalCer treatment must be a good candidate for human liver cancer treatment.

Recently, activated DC have been implicated in the activation of NKT and NK cells in both mice and humans,^{1,5,8-12,22} suggesting that DC play crucial roles in the activation of abundant immune cells in the liver. To establish more efficient α -GalCer treatment in liver cancer, the precise mechanism of liver DC activation is needed. Our results demonstrated that the proportion of liver DC in liver MNC increased immediately and reached the peak 1 day after α -GalCer treatment. The infiltration of tumors by mature DC has been reported to correlate with a better prognosis in cancer patients.^{23,24} Thus, the increase of liver DC by α -GalCer might contribute to generation of antitumor effect against liver cancer. The expressions of co-stimulatory

molecules on liver DC also increased early after administration of α -GalCer. IL-12 production from DC is key Th1-cytokine to enhance NK and CTL functionality,^{25,26} IL-12 production from liver DC after α -GalCer treatment was significantly higher than that after vehicle treatment.¹⁷ These results suggested that α -GalCer treatment resulted in rapid activation of liver DC, which might play important roles in activating liver NK cells and might contribute to the subsequent establishment of acquired immunity against liver cancer. Pillarisetty *et al.* identified new DC subsets, NK-DC, which presented in the liver of mice,²⁷ which may affect the interpretation of the activation of liver NK cells by α -GalCer. However, we previously demonstrated that α -GalCer had no direct effect on liver NK cells in mice.⁴ These results supported the idea that α -GalCer activated liver DC, which activated the liver NK cells secondary.

Interferon- γ ELISPOT assay revealed that the frequency of CD8⁺ T cells isolated from α -GalCer-treated mice in liver tumors in response to p53₂₃₂₋₂₄₀ peptide were much higher than that from vehicle-treated mice. Mayordomo *et al.* reported that immunization of p53₂₃₂₋₂₄₀ peptide-pulsed DC induced peptide-specific CTL in immunized mice that showed cytolytic activity against CMS4, p53 overexpressing cells.¹⁸ In this study, ⁵¹Cr-release assay demonstrated that CD8⁺ T cell, not CD4⁺ T cells, played essential roles in the cytolytic activity against CMS4 cells in α -GalCer-treated mice, which is consistent with the IFN- γ ELISPOT results. The detection of p53₂₃₂₋₂₄₀ peptide-specific CTL means the generation of CMS4 tumor-specific CTL after eradication of liver tumor by α -GalCer treatment. The activation of NKT cells was associated with an expansion of antigen-specific CTL, as might be expected if the DC that matured *in vivo* in response to NKT cells were capturing antigens.²⁸⁻³¹ Our results suggested that the activation of hepatic DC might be associated with the efficiency of generation of tumor antigen-specific CTL.

Additional experiments using an s.c. re-challenge with tumor demonstrated that α -GalCer treatment of liver tumors not only blocked treated CMS4 liver tumor progression but completely protected against consequent "recurrence" of that same tumor at a distant site. In contrast, Colon26 re-challenge tumor was not inhibited in treated mice, suggesting that CMS4-specific immunity was generated after liver tumor treatment. These results were consistent with the activation of acquired immunity evaluated by IFN- γ ELISPOT assay with increase of the frequency of p53₂₃₂₋₂₄₀ peptide-specific CTL. Taken together, we believe that α -GalCer treatment of liver

tumors resulted in rejection of both local liver tumor and distant metastatic tumor.

In summary, we have shown that α -GalCer treatment activated both innate and acquired immune cells in the liver. These findings suggested that the use of α -GalCer might represent a particularly promising approach to suppress tumor growth and to promote regression of metastatic lesions in liver cancer patients.

ACKNOWLEDGMENTS

THIS WORK WAS supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a Grant-in-Aid for Research on Hepatitis and BSE from the Ministry of Health, Labour and Welfare of Japan.

REFERENCES

- 1 Kawano T, Cui J, Kozuka Y *et al.* CD1d-restricted and TCR-mediated activation of V α 14NKT cells by glycosylceramides. *Science* 1997; 278: 1626–9.
- 2 Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN- γ producing NKT response induced with alpha-galactosylceramide-loaded DCs. *Nat Immunol* 2002; 3: 867–74.
- 3 Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M *et al.* α -Galactosylceramide-activated V α 14 natural killer T cells mediate protection against murine malaria. *Proc Natl Acad Sci USA* 2000; 97: 8461–6.
- 4 Miyagi T, Takehara T, Tatsumi T *et al.* CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. *Int J Cancer* 2003; 106: 81–9.
- 5 Giaccone G, Punt CJ, Ando Y *et al.* A phase I study of the natural killer T-cell ligand α -galactosylceramide (KRN7000) in patients with solid tumors. *Clin Cancer Res* 2002; 8: 3702–9.
- 6 Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. *Immunol Rev* 2000; 174: 5–20.
- 7 Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. *Gastroenterology* 2001; 120: 250–60.
- 8 Steinman RM. The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 1991; 9: 271–96.
- 9 Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. *Blood* 1997; 90: 3245–87.
- 10 Fernandez NC, Lozier A, Flament C *et al.* Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses *in vivo*. *Nat Med* 1999; 5: 405–11.

- 11 Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. *J Exp Med* 2002; 195: 327–33.
- 12 Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting NK cells and are recognized via the Nkp30 receptor by activated NK cells. *J Exp Med* 2002; 195: 343–51.
- 13 Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. *J Exp Med* 2002; 195: 335–41.
- 14 Miller G, Lahrs S, Dematteo RP. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. *FASEB J* 2003; 17: 728–30.
- 15 Kawano T, Cui J, Koezuka Y *et al.* Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated V α 14NKT cells. *Proc Natl Acad Sci USA* 1998; 95: 5690–3.
- 16 Kitamura H, Iwakabe K, Yahata T *et al.* The natural killer T (NKT) cell ligand α -galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. *J Exp Med* 1999; 189: 1121–8.
- 17 Sasakawa A, Tatsumi T, Takehara T *et al.* Activated liver dendritic cells generates strong acquired immunity in α -galactosylceramide treatment. *J Hepatol* 2009; 50: 1155–62.
- 18 Mayordomo JI, Loftus DJ, Sakamoto H *et al.* Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. *J Exp Med* 1996; 183: 1357–65.
- 19 Tatsumi T, Huang J, Gooding WE *et al.* Intratumoral delivery of dendritic cells engineered to secrete both interleukin(IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. *Cancer Res* 2003; 63: 6378–86.
- 20 Uemura A, Takehara T, Miyagi T *et al.* Natural killer cell is a major producer of IFN- γ that is critical for the IL-12-induced anti-tumor effect in mice. *Cancer Immunol Immunother* 2010; 59: 453–63.
- 21 Yamaguchi S, Tatsumi T, Takehara T *et al.* Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide pulsed dendritic cell vaccines. *Cancer* 2007; 110: 1469–77.
- 22 Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. *J Immunol* 2004; 172: 1333–9.
- 23 Takagi S, Miyagawa S, Ichikawa E *et al.* Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. *Hum Pathol* 2004; 35: 881–6.
- 24 Iwamoto M, Shinohara H, Miyamoto A *et al.* Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. *Int J Cancer* 2003; 104: 92–7.
- 25 Kobayashi M, Fitz L, Ryan M *et al.* Identification and purification of natural killer cell stimulatory factors (NKSF), a cytokine with multiple biological effects on human lymphocytes. *J Exp Med* 1989; 170: 827–45.
- 26 Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. *Cell Immunol* 1992; 143: 127–42.
- 27 Pillarisetty VG, Katz SC, Bleier JI, Shah AB, DeMatteo RP. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN- γ via autocrine IL-12. *J Immunol* 2005; 174: 2612–18.
- 28 Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α -galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. *J Exp Med* 2003; 198: 267–79.
- 29 Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. *J Exp Med* 2004; 199: 1607–18.
- 30 Hermans IF, Silk JD, Gileadi U, Salio M *et al.* NKT cells enhance CD4+ and CD8+ T cells responses to soluble antigen in vivo through direct interaction with dendritic cells. *J Immunol* 2003; 171: 5140–7.
- 31 Nishimura T, Kitamura H, Iwakabe K *et al.* The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. *Int Immunol* 2000; 12: 987–94.

Amino Acid Substitution in the Core Protein has no Impact on Relapse in Hepatitis C Genotype 1 Patients Treated With Peginterferon and Ribavirin

Yuko Inoue,¹ Naoki Hiramatsu,^{1*} Tsugiko Oze,¹ Takayuki Yakushijin,¹ Kiyoshi Mochizuki,¹ Kazuto Fukuda,² Eiji Mita,³ Yoshimichi Haruna,⁴ Atsuo Inoue,⁴ Yasuharu Imai,² Atsushi Hosui,¹ Takuya Miyagi,¹ Yuichi Yoshida,¹ Tomohide Tatsumi,¹ Shinichi Kiso,¹ Tatsuya Kanto,¹ Akinori Kasahara,¹ Tetsuo Takehara,¹ and Norio Hayashi⁵

¹Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan

²Ikeda Municipal Hospital, Ikeda, Japan

³National Hospital Organization Osaka National Hospital, Osaka, Japan

⁴Osaka General Medical Center, Osaka, Japan

⁵Kansai Rousai Hospital, Amagasaki, Japan

Previous reports demonstrated that amino acid (aa) substitutions in the hepatitis C virus (HCV) core protein are predictors of non-virological responses to pegylated interferon (Peg-IFN) and ribavirin combination therapy. The aim of this study was to investigate the impact of core aa substitutions on viral kinetics during the treatment and relapse after the treatment. The 187 patients with HCV genotype 1 enrolled in this study were categorized into four groups according to core aa substitution patterns: double-wild group (n=92), Arg70/Leu91; 70-mutant group (n=42), Gln70/Leu91; 91-mutant group (n=31), Arg70/Met91; and double-mutant group (n=22), Gln70/Met91. The relationship between the core aa substitutions and the virological response was examined. Multivariate logistic regression analyses showed that substitution at aa 70 was significantly associated with a poor virological response during the first 12 weeks (decline of <1 log from baseline at week 4, <2 log at week 12), and substitution at aa 91 was significantly associated with detectable HCV RNA at week 24. With respect to relapse, only the ribavirin exposure (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.60–0.98) and HCV RNA disappearance between weeks 13 and 24 (OR, 23.69; 95% CI, 5.44–103.08) were associated independently with relapse, with no correlation being found with the core aa substitutions and relapse. In conclusion, the results showed that core aa substitutions can be strong predictive factors at pretreatment of the non-response, but not for relapse, for virological responders with HCV RNA disappearance during treatment. **J.**

Med. Virol. 83:419–427, 2011. © 2011 Wiley-Liss, Inc.

KEY WORDS: amino acid substitution; core protein; hepatitis C virus; peginterferon and ribavirin combination therapy; relapse

INTRODUCTION

The current standard of care for chronic hepatitis C patients is combination therapy using pegylated interferon (Peg-IFN) and ribavirin [Anonymous, 2002; Strader et al., 2004; Dienstag and McHutchison, 2006]. However, the treatment outcome in response to this combination therapy among patients infected with hepatitis C virus (HCV) genotype 1 is still unsatisfactory and the chance of sustained virological response ranges from 42% to 52% [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004]. Therefore, tailoring treatment regimens for individual patients has become an important issue.

Grant sponsor: Ministry of Health Labor and Welfare of Japan (Research on Hepatitis and BSE); Grant sponsor: Scientific Research from the Ministry of Education, Science, and Culture of Japan.

*Correspondence to: Naoki Hiramatsu, MD, PhD, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: hiramatsu@gh.med.osaka-u.ac.jp

Accepted 20 September 2010

DOI 10.1002/jmv.21975

Published online in Wiley Online Library (wileyonlinelibrary.com).

Outcome of therapy is influenced by various factors. Some host factors, such as age, sex, body weight, insulin resistance, and liver fibrosis have been reported as pretreatment factors affecting virological response to this combination therapy [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004; Romero-Gomez et al., 2005]. Recently, several genome-wide association studies identified single nucleotide polymorphisms (SNPs) near the interleukin (IL)-28B gene, which encodes interferon (IFN) lambda-3, as associated with response to Peg-IFN plus ribavirin treatment among patients infected with HCV of European [Suppiah et al., 2009], African [Ge et al., 2009], and Asian ancestry [Tanaka et al., 2009]. These studies suggest that host genetic variants may be associated strongly with response to IFN-alpha-based therapy. However, the ethical problem to perform host genetic search for all patients remains, and the sustained virological response rate is only 48–69% in patients having favorable IL-28B genotype to this combination therapy [Thompson et al., 2010].

Response-guided therapy is a dynamic approach to management of chronic hepatitis C patients based on the virological response at weeks 4 and 12 of treatment. At present, it is regarded as an excellent strategy for optimizing the treatment duration for individual patients. Earlier HCV RNA disappearance has been shown to lead to a higher sustained virological response rate [Ferenci et al., 2005; Berg et al., 2006; McHutchison et al., 2009], while patients without an early virological response, defined as showing an at least 2 log decrease from the baseline of HCV RNA levels at week 12 is recommended for discontinuing the treatment under the current guidelines [Anonymous, 2002; Strader et al., 2004; Dienstag and McHutchison, 2006].

In addition to viral kinetics during treatment, other viral factors have also been reported to be associated with this combination therapy outcome [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004; Shirakawa et al., 2008]. Previous studies indicated that amino acid (aa) 70 and/or 91 substitutions in the HCV core protein were independent pretreatment predictors of null or weak response to this combination therapy in genotype 1 patients [Akuta et al., 2007b,c]. The HCV core protein has been reported to inhibit signal transducer and activator of transcription (STAT)-1 phosphorylation, and disrupt the normal IFN-stimulated transcriptional response to viral infection [Lin et al., 2006]. It is supposed that the HCV core region might be associated with resistance to IFN therapy involving the Janus activated kinase (Jak)-STAT signaling cascade [Blindenbacher et al., 2003; Bode et al., 2003; Melen et al., 2004; de Lucas et al., 2005]. Recently, Okanoue et al. [2009] have demonstrated that wild type of core aa 70 and 91 are important for positive prediction of the virological response. However, the impact of core aa substitutions on the extent of HCV RNA decline during the treatment or virological relapse after completion of treatment has not yet been investigated in detail. Approximately 30% of genotype 1 patients who become

HCV RNA negative at the end of the treatment will experience relapse [Hadziyannis et al., 2004]. Being able to distinguish between end-of-treatment responders with a high probability of relapse and those with a low probability of relapse will be useful in reducing relapse rates and improving treatment outcome.

The aim of this study was to evaluate the impact of aa substitutions in the HCV core protein on viral kinetics and virological relapse in patients with HCV genotype 1 treated by Peg-IFN alpha-2b and ribavirin combination therapy.

PATIENTS AND METHODS

Patient Selection and Study Design

Patients considered to be eligible for this study were those who were infected with HCV genotype 1, had a viral load more than 10^5 IU/ml, had started Peg-IFN alpha-2b (Schering-Plough K.K. Tokyo, Japan) and ribavirin (Schering-Plough K.K.) combination therapy from December 2005 to June 2008 at Osaka University Hospital and three other medical institutions taking part in the Osaka Liver Forum, and had been examined with respect to the aa sequences at positions 70 and 91 in the HCV core protein with pretreatment serum samples. Patients with the following criteria were excluded: hepatitis B virus or human immunodeficiency virus co-infection; decompensated liver disease; severe cardiac, renal, hematological, or chronic pulmonary disease; poorly controlled psychiatric disease; poorly controlled diabetes; and immunologically mediated disease. As a result of screening at the institutions concerned, 187 patients with HCV genotype 1 were enrolled in this study. Liver biopsy had been performed within 12 months prior to the treatment, and histological results were classified according to the METAVIR scoring system [Bedossa and Poynard, 1996].

Written informed consent was obtained from each patient, and the study protocol was reviewed and approved according to the ethical guidelines of the 1975 Declaration of Helsinki by Institutional Review Boards at the respective sites.

Peg-IFN alpha-2b and ribavirin dosages were based on body weight according to the manufacturer's instructions: Peg-IFN alpha-2b was given subcutaneously weekly (45 kg or less, 60 µg/dose; 46–60 kg, 80 µg/dose; 61–75 kg, 100 µg/dose; 76–90 kg, 120 µg/dose; and 91 kg or more, 150 µg/dose), and ribavirin was given orally daily (60 kg or less, 600 mg/day; 61–80 kg, 800 mg/day; and 81 kg or more, 1,000 mg/day). The drug doses were also modified based on the manufacturer's instructions according to the severity of the adverse hematologic effects.

Detection of Amino Acid Substitutions in Core Region

The nucleotide sequence encoding aa 1–191 (the core protein of HCV) was analyzed by direct sequencing as described by Akuta et al. [2005, 2007b]. In brief, HCV

RNA was extracted from the serum samples and converted to cDNA and two nested rounds of polymerase chain reaction (PCR) were performed. Primers used in the PCR were as follows: the first PCR was performed using cc11 (sense, 5'-GCCATA GTG GTC TGC GGA AC-3') and e14 (antisense, 5'-GGA GCA GTC CTT CGT GAC ATG-3') primers. The second PCR was performed using cc9 (sense, 5'-GCT AGC CGA GTA GTG TT-3') and e14 (antisense) primers. All samples were denatured initially at 95°C for 15 min. The 35 cycles of amplification were set as follows: denaturation for 1 min at 94°C, annealing of primers for 2 min at 55°C, and extension for 3 min at 72°C with an additional 7 min for extension. Then 1 µl of the first PCR product was transferred to the second PCR reaction. The conditions for the second PCR were the same as the first PCR, except that the second PCR primers were used instead of the first PCR primers. The amplified PCR products were purified by the QIA quick PCR Purification Kit (Qiagen, Tokyo, Japan) after agarose gel electrophoresis and then used for direct sequencing. Dideoxynucleotide termination sequencing was performed with the Big Dye Deoxy Terminator Cycle Sequencing Kit (Perkin-Elmer, Tokyo, Japan). The obtained nucleotide and amino acid sequences were compared with the prototype sequence of genotype 1b HCV-J (GenBank Accession No. D90208) [Kato et al., 1990]. Wild types virus encoded arginine (Arg) and leucine (Leu) at aa 70 and 91, respectively, and the aa substitutions were glutamine (Gln) or histidine (His) at aa 70 and methionine (Met) at aa 91. If the intensities of the band were similar, the case was regarded as competitive. Two patterns of mutant and competitive were labeled as mutant. In this study, patients were categorized into four groups according to aa substitution patterns: double-wild group, Arg70/Leu91; 70-mutant group, Gln or His70/Leu91; 91-mutant group, Arg70/Met91; and double-mutant group, Gln or His70/Met91.

Virological Tests

Serum HCV RNA level was quantified by PCR assay (COBAS Amplicor HCV Monitor Test v2.0, Chugai-Roche Diagnostics, Tokyo, Japan), with a sensitivity limit of 5,000 IU/ml and a dynamic range from 5,000 to 5,000,000 IU/ml.

Serum HCV RNA was assessed by qualitative PCR assay (COBAS Amplicor HCV Test v2.0, Chugai-Roche Diagnostics), with a detection limit of 50 IU/ml.

Efficacy Assessments

Patients who achieved negative HCV RNA at week 12 were defined as having a complete early virological response. Patients who became HCV RNA negative between weeks 13 and 24 were defined as having a late virological response. According to the established guidelines, the treatment was considered to have failed if the patients showed an insufficient virological response at week 12 (a detectable HCV RNA and a decrease of <2 log from the baseline level) or at week 24 (a detectable

HCV RNA), and therapy was discontinued. The end-of-treatment response was defined as undetectable HCV RNA at week 48. Patients with end-of-treatment response and undetectable HCV RNA 24 weeks after completion of therapy were defined as having sustained virological response. Relapse was defined as a case in which HCV RNA had been undetectable at the end-of-treatment, but detectable during the 24-week follow-up after the treatment.

Drug Exposure

The amounts of Peg-IFN alpha-2b and ribavirin actually taken by each patient during the treatment period were evaluated by reviewing the medical records. The mean doses of both drugs were calculated individually as averages on the basis of body weight at baseline; Peg-IFN alpha-2b expressed as µg/kg/week and ribavirin as mg/kg/day.

Data Collection

The medical records were retrospectively reviewed and the factors necessary for this examination were extracted: age, sex, body weight, body mass index (BMI), basic laboratory assessments, liver histology, quantitative and qualitative HCV RNA, dose of Peg-IFN alpha-2b and ribavirin received at each administration, and the response to treatment.

Statistical Analysis

Continuous variables are reported as the mean with standard deviation (SD) or median level, while categorical variables are shown as the count and proportion. In univariate analysis, the Mann-Whitney *U*-test (between two groups) or Kruskal-Wallis test (among more than three groups) was used to analyze continuous variables, while chi-squared and Fisher's exact tests were used for analysis of categorical data. For all tests, two-sided *P* values were calculated, and the results were considered statistically significant if $P < 0.05$. Variables that achieved statistical significance ($P < 0.05$) or marginal significance ($P < 0.10$) on univariate analysis were subjected to multivariate logistic regression analysis. Stepwise and multivariate logistic regression models were used to explore the independent factors that could be used to predict a virological response. Statistical analysis was performed using the SPSS program for Windows, version 15.0J (SPSS, Chicago, IL).

RESULTS

Baseline Characteristics of Study Groups

The total study population was predominately male (55.6%), with a mean age of 56.2 years. The baseline characteristics of all patients and the four study groups according to core aa substitution patterns are shown in Table I. Mean age of patients in the double-mutant group was higher than the other three groups ($P = 0.003$). More patients in the double-wild group had

TABLE I. Baseline Demographic and Viral Characteristics of Patients

Characteristic	Total (n = 187)	Double-wild (n = 92)	70-Mutant (n = 42)	91-Mutant (n = 31)	Double-mutant (n = 22)	P value ^a
Age (years)	56.2 ± 9.3	55.7 ± 9.2	57.0 ± 9.8	52.4 ± 9.9	61.8 ± 4.7	0.003
Sex (male/female)	104/83	51/41	26/16	18/13	9/13	0.444
Body weight (kg)	60.9 ± 11.6	60.9 ± 11.7	62.2 ± 11.7	62.5 ± 13.2	56.0 ± 7.5	0.193
Body mass index (kg/m ²)	22.8 ± 3.1	22.8 ± 3.0	22.8 ± 3.1	23.1 ± 3.6	22.1 ± 2.4	0.627
Past IFN therapy (naive/experienced)	118/69	45/47	34/8	20/11	19/3	<0.001
HCV RNA ($\times 10^3$ IU/ml) ^b	1,700	2,100	1,400	1,500	1,230	0.122
Fibrosis (0–2/3–4) ^c	105/29	56/11	22/6	14/7	13/5	0.366
Activity (0–1/2–3) ^d	83/50	42/24	18/10	11/10	12/6	0.771
White blood cell ($\times 10^6/l$)	4,980 ± 1,520	4,990 ± 1,420	5,180 ± 1,760	4,890 ± 1,430	4,660 ± 1,560	0.795
Red blood cell ($\times 10^{12}/l$)	4.34 ± 0.46	4.33 ± 0.46	4.41 ± 0.52	4.39 ± 0.42	4.18 ± 0.32	0.145
Hemoglobin (g/dl)	13.9 ± 1.4	13.9 ± 1.4	14.0 ± 1.7	14.2 ± 1.4	13.5 ± 1.1	0.253
Platelet ($\times 10^9/l$)	161 ± 54	167 ± 49	165 ± 65	154 ± 60	138 ± 30	0.067
ALT (IU/l)	74 ± 61	73 ± 67	79 ± 56	81 ± 64	57 ± 37	0.263
γ -GTP (IU/l)	62 ± 74	47 ± 54	81 ± 89	70 ± 93	78 ± 78	0.032

IFN, interferon; HCV, hepatitis C virus; ALT, alanine aminotransferase; γ -GTP, gamma-glutamyl transpeptidase.

^aP value for comparison among double-wild, 70-mutant, 91-mutant, and double-mutant.

^bValues expressed as median.

^cData for 53 patients are missing.

^dData for 54 patients are missing.

been treated previously for HCV infection ($P < 0.001$). Patients in the double-wild group had significantly lower gamma-glutamyl transpeptidase (γ -GTP) levels ($P = 0.032$).

Progress of Patients

The progress of patients in this study is shown in Figure 1. Of the 187 patients, 183 completed 4 weeks of treatment. Among them, 133 were assessed based on HCV RNA dynamics between baseline and week 4.

Those completing 12 weeks of treatment totaled 181, of which 154 were assessed for HCV RNA dynamics between baseline and week 12. Those completing 24 weeks of treatment totaled 153, and all were assessed for HCV RNA quantitatively or qualitatively at week 24. Those completing 48 weeks of treatment totaled 114. These 114 patients and the 55 patients who had discontinued treatment because of treatment failure entered a follow-up period. Among these 169 patients, 164 completed 24 weeks follow-up and the sustained virological response (SVR) rate




Fig. 1. Treatment and follow-up of the study patients. Treatment was discontinued for patients with <2 log decrease from the baseline HCV RNA level at week 12 or detectable HCV RNA at week 24.

TABLE II. Multivariate Analysis for Factors Associated With <1 log Decrease in HCV RNA Level at Week 4, <2 log Decrease at Week 12, Detectable HCV RNA at Week 24, and Relapse After Treatment

Factor	Category	Odds Ratio	95% CI	P value
HCV RNA <1 log decrease at week 4				
White blood cells ($\times 10^6/l$)	<5,000/5,000 \leq	—	—	NS
γ -GTP (IU/l)	<40/40 \leq	—	—	NS
Peg-IFN dose (μ g/kg/week)	By 0.1 μ g/kg/week	0.80	0.67–0.97	0.020
Core aa 70	Wild/mutant	1/2.80	1.16–6.75	0.022
HCV RNA <2 log decrease at week 12				
γ -GTP (IU/l)	<40/40 \leq	—	—	NS
Peg-IFN dose (μ g/kg/week)	By 0.1 μ g/kg/week	—	—	NS
Core aa 70	Wild/mutant	1/2.72	1.09–6.78	0.032
Detectable HCV RNA at week 24				
Platelet ($\times 10^9/l$)	<150/150 \leq	—	—	NS
γ -GTP (IU/l)	<40/40 \leq	1/2.46	1.02–5.95	0.045
Core aa 91	Wild/mutant	1/4.11	1.73–9.78	0.001
Relapse after treatment				
Ribavirin dose (mg/kg/day)	By 1 mg/kg/day	0.77	0.60–0.98	0.036
Virological response	Complete early virological response/late virological response	1/23.69	5.44–103.08	<0.001

CI, confidence interval; NS, not significant difference; γ -GTP, gamma-glutamyl transpeptidase; Peg-IFN, pegylated interferon; aa, amino acid.

was 48.2% (79/164), based on per-protocol set. Among the 106 patients who had an end-of-treatment response and completed follow-up, 27 showed relapse during the follow-up period; the relapse rate was 25.5% (27/106).

IMPACT OF CORE-RELAPSE AFTER TREATMENT (TABLE II)

Impact of core aa substitutions on <1 log viral decrease rate at week 4, <2 log at week 12, detectable HCV RNA at week 24, and virological relapse after treatment (Table II).

The impact of core aa substitutions on <1 log viral decrease rate at week 4, <2 log at week 12, detectable HCV RNA at week 24, and virological relapse after treatment (Table II).

The impact of the core aa substitutions on <1 log viral decrease at week 4, which is a predictor of non-sustained virological response; fewer than 5% of patients without 1 log decrease at week 4 had an sustained virological response [McHutchison et al., 2009] was examined. Among the 133 patients who completed 4 weeks of treatment, 31 failed to show a ≥ 1 log decrease of HCV RNA level at week 4. Univariate analysis for factors associated with <1 log decrease of HCV RNA level at week 4 was performed on the following variables: age, sex, body weight, BMI, history of past IFN therapy, baseline HCV RNA level, histological fibrosis and activity, white blood cell count, red blood cell count, hemoglobin level, platelet count, alanine aminotransferase (ALT) level, γ -GTP level, dose exposure of Peg-IFN and ribavirin, and aa substitutions in the HCV core protein. The results indicated that pretreatment white blood cell count, γ -GTP level, the mean dose of Peg-IFN during the first 4 weeks of treatment and single-spot substitution in the HCV RNA core position at aa 70 contributed to a <1 log decrease of HCV RNA level at week 4. Analysis of

these factors by multivariate logistic regression analysis showed that substitution of aa 70 (odds ratio (OR) 2.80, 95% confidence interval (CI) 1.16–6.75, $P = 0.022$) as well as the mean dose of Peg-IFN (OR 0.80, 95% CI 0.67–0.97, $P = 0.020$) was independently associated with viral decline (<1 log) at week 4.

Next, the impact of the core aa substitutions on <2 log viral decrease rate at week 12, which is presently considered to be the most reliable predictor of non-sustained virological response [Fried et al., 2002; Davis et al., 2003] was examined. Among the 154 patients who completed 12 weeks of treatment, 25 failed to show a ≥ 2 log decrease of HCV RNA level at week 12. Univariate analysis was performed on the same factors in the preceding examination. As a result, pretreatment γ -GTP level, the mean dose of Peg-IFN during the first 12 weeks of treatment and single-spot substitution in the HCV RNA core position at aa 70 contributed to a <2 log decrease of the HCV RNA level. These factors were then analyzed by multivariate logistic regression analysis; only substitution of aa 70 (OR 2.72, 95% CI 1.09–6.78, $P = 0.032$) was found to be independently associated with an insufficient virological response (<2 log HCV RNA decrease from baseline level) at week 12.

The impact of the core aa substitutions on detectable HCV RNA at week 24, which is another non-sustained virological response predictor [Davis et al., 2003] was also examined. Among 153 patients who completed 24 weeks of treatment, 30 still had detectable HCV RNA at week 24. Univariate analysis revealed that pretreatment platelet count, γ -GTP level, and single-spot substitution in the HCV RNA core position at aa 91 contributed to the HCV RNA remaining positive. Multivariate logistic regression analysis, using these factors, indicated that substitution of aa 91 (OR 4.11, 95% CI 1.73–9.78, $P = 0.001$) as well as γ -GTP level (> 40 IU/l) (OR 2.46, 95% CI 1.02–5.95, $P = 0.045$) was

independently associated with detectable HCV RNA at week 24.

Next, the factors associated with virological relapse after the treatment was examined. Univariate analysis was performed on the virological response (complete early virological response or late virological response) in addition to the factors in the preceding examination, revealing the mean dose of ribavirin during the full treatment period and a late virological response, but not aa substitutions (single-spot substitution in the HCV RNA core position at aa 70, $P = 0.467$; aa 91, $P = 0.776$).




Fig. 2. Relapse rates according to the timing of HCV RNA disappearance (A), mean ribavirin dose (B), and core amino acid substitution patterns (C) in patients who had end-of-treatment response and completed 24-week follow-up. Relapse rates are shown as percentages and the number of patients with relapse in relation to the total number of patients examined is shown at the top of each column. Gray bar, sustained virological response; black bar, relapse.

These factors were analyzed by multivariate logistic regression analysis. This analysis revealed that the mean ribavirin dose (OR 0.77, 95% CI 0.60–0.98, $P = 0.036$) and a late virological response (OR 23.69, 95% CI 5.44–103.08, $P < 0.001$) were independently associated with relapse.

Relapse Rates According to the Timing of HCV RNA Disappearance, Ribavirin Dose, and Core aa Substitution Patterns

The relapse rates were indicated according to the time to the first non-detection of HCV RNA, mean ribavirin dose and core aa substitution patterns (Fig. 2). The relapse rate was 0% (0/10) in patients with undetectable HCV RNA during 1–4 weeks, and increased 13.3% (6/45) during 5–8 weeks, 25.9% (7/27) during 9–12 weeks, 40% (2/5) during 13–16 weeks, 100% (6/6) during 17–20 weeks, and 100% (3/3) during 21–24 weeks (Fig. 2A). Similarly, the relapse rates increased as the mean ribavirin dose decreased; 13.3% (2/15) in patients receiving ≥ 12 mg/kg/day of ribavirin, 21.1% (8/38) at 10–12 mg/kg/day, 28.6% (8/28) at 8–12 mg/kg/day, and 36% (9/25) at < 8 mg/kg/day (Fig. 2B). On the other hand, the relapse rates were similar among the four core aa substitution patterns; 23.0% (14/61) in patients in the double-wild group, 36% (9/25) in 70-mutant group, 23.1% (3/13) in 91-mutant group, and 14.3% (1/7) in double-mutant group (Fig. 2C). In the subgroup of patients receiving < 10 mg/kg/day of ribavirin, no significant difference of the relapse rates was observed between double-wild group and 70-mutant and/or 91-mutant group (31.3% (10/32) in double-wild group vs. 33.3% (7/21) in 70-mutant and/or 91-mutant group), and also in the patients receiving ≥ 10 mg/kg/day of ribavirin (13.8% (4/29) in double-wild group vs. 25% (6/24) in 70-mutant and/or 91-mutant group) (Fig. 3). Among patients with complete early virological response, the relapse rates were also similar between double-wild group and 70-mutant and/or 91-mutant group (13.7% (7/51) in double-wild vs. 18.4% (7/38) in 70-mutant and/or 91-mutant group). The impact of core aa substitutions on relapse rates in patients with late virological response could not be assessed because of the small number of patients.

DISCUSSION

Kobayashi et al. [2010] investigated the clinical and virological factors influencing these core aa substitutions in patients infected with HCV genotype 1 who had not received antiviral therapy, and found that HCV variants with wild type of core aa 70 and 91 significantly decreased with age, while those with the mutant type of core aa 70 and/or 91 significantly increased with age. Furthermore, they demonstrated that the proportion of patients with the mutant type of core aa 70 HCV variant significantly increased with an elevated γ -GTP level and a decrease in platelet counts. In this study, the significant differences of baseline demographics between patient groups according to core aa substitution pat-




Fig. 3. Relapse rates according to core amino acid substitution patterns in patients receiving <10 mg/kg/day and receiving \geq 10 mg/kg/day of ribavirin. Relapse rates are shown as percentages and the number of patients with relapse in relation to the total number of patients examined is shown at the top of each column. Gray bar, sustained virological response; black bar, relapse.

terns were similarly found in age, platelet count, and γ -GTP level. Accordingly, this study cohort had no specific bias and seems to reflect the natural background of the patients according to the HCV variance. In this study, the impact of HCV core aa substitutions on the virological response were evaluated by multivariate analysis, in order to resolve the bias of patient background factors among the groups classified according to the core aa substitution patterns. Recently, Abe et al. [2010] reported that the human genotype of the rs8099917 SNP at the IL28B locus was associated with lower γ -GTP level and viral wild type of core aa 70 and 91. Possibly these differences of IL28B genotype may influence the difference of patient background factors. Further studies are needed to clarify the relationship between human genetic variation and HCV core amino acid substitutions.

The HCV core protein has been reported to have an effect on a variety of cellular functions [Lai and Ware, 2000; Joo et al., 2005; Ariumi et al., 2007; Waris et al., 2007; Osna et al., 2008]. Currently, aa substitutions in the HCV core region has been thought to be related with outcome of antiviral therapy [Akuta et al., 2005; Donlin et al., 2007] and also the development of hepatocellular carcinoma [Akuta et al., 2007a; Hu et al., 2009]. Importance of core aa substitutions, especially at aa 70 and 91, comes to be recognized, and the new method to detect these substitutions easily has been proposed [Nakamoto et al., 2009]. As for the mechanism of antiviral activity on core aa substitutions, Ikeda et al. [2010] showed that core aa substitutions were not associated with intracellular antiviral response to IFN-alpha by in vitro analysis. The mechanism of antiviral activity and hepatocarcinogenesis on core aa substitutions has not been elucidated enough, so far. Further in vitro studies will be needed to clarify this.

Previous studies showed that patients with substitution of core aa 70 often had slow or no decrease in HCV RNA levels during the early phase of IFN-alpha treatment [Akuta et al., 2005, 2007b,c; Donlin et al., 2007]. Consistent with these reports, multivariate analysis in this study revealed that substitution of core aa 70 could be independently associated with insufficient viral decline during the first 12 weeks after the treatment (decline of <1 log from baseline at week 4, <2 log at week 12). This suggests that patients with substitution of core aa 70 are likely to fail to have a sustained virological response. On the other hand, dose exposure of Peg-IFN during the first 4 weeks of treatment was also independently linked to a minimal decline in HCV RNA (<1 log) at week 4 in this study. This suggests that maintaining the dose of Peg-IFN as high as possible until the disappearance of HCV RNA can help avoid treatment failure [McHutchison et al., 2002; Oze et al., 2009], especially in patients with substitution of core aa 70. On the other hand, substitution of core aa 91 was independently associated with detectable HCV RNA at week 24. This suggests that patients with substitution of core aa 91 are likely to achieve non-sustained virological response even if they had a \geq 2 log decline in the HCV RNA level at week 12. The reason for the difference of the impact on virological response is not yet clear.

Multivariate logistic regression analysis also showed that the dose exposure of ribavirin during the full treatment period and having late virological response were independently associated with relapse. As for ribavirin exposure, it has been previously demonstrated that the relapse rate among patients responding to the treatment showed a decline in relation to the increase in the dose of ribavirin [Hiramatsu et al., 2009]. In this study, relapse rates were also decreased from 36% to 13.3% with increasing dose exposure of ribavirin among patients with end-of-treatment response. These results

confirm that maintaining a sufficient dose of ribavirin during the full treatment period could reduce the possibility of relapse, and that an extended duration of therapy for patients with late virological response could increase the chance of achieving sustained virological response, regardless of core aa substitution patterns [Berg et al., 2006; Pearlman et al., 2007; Ferenci et al., 2010].

In this study, the COBAS Amplicor HCV Test v2.0, with a lower limit of detection of 50 IU/ml, was used to assess the serum HCV RNA. Recently, real-time PCR-based HCV RNA assays with a higher sensitivity, COBAS TaqMan HCV assay (Chugai-Roche Diagnostics), with a lower limit of detection of 15 IU/ml, have been introduced. Sarrazin et al. [2010] compared virological response rates that were originally tested by COBAS Amplicor assay with those retested by COBAS TaqMan assay, using the same cohort. Among genotype 1 patients, complete early virological response and sustained virological response rates were similar when virological responses were defined as <50 IU/ml by Amplicor assay (77% and 87%) and <15 IU/ml by TaqMan assay (76% and 88%). Therefore, measuring HCV RNA by the Amplicor assay in this study would have little effects on the results.

In conclusion, the results have demonstrated that substitution of core aa 70 could be independently associated with an insufficient decline in HCV RNA level during first 12 weeks, and substitution of core aa 91 was independently associated with detectable HCV RNA at week 24, all of which were considered to be important negative predictors of attaining sustained virological response in patients with HCV genotype 1 treated with Peg-IFN plus ribavirin. On the other hand, only dose exposure of ribavirin and no complete early virological response was independent predictors of virological relapse among patients with end-of-treatment response, not substitution of core aa 70 or 91. The aa substitution patterns of the HCV core protein can be an important pretreatment predictor for non-response in patients with HCV genotype 1 treated with Peg-IFN plus ribavirin, but not for relapse after the completion of therapy.

REFERENCES

- Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arihiro K, Kubo M, Nakamura Y, Chayama K. 2010. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. *J Hepatol* 53:439–443.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372–380.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *Hepatology* 46:1357–1364.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 46:403–410.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007c. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 79:1686–1695.
- Anonymous. 2002. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10–12, 2002. *Hepatology* 36:S3–S20.
- Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N. 2007. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. *J Virol* 81:13922–13926.
- Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 24:289–293.
- Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. 2006. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 130:1086–1097.
- Blindenbacher A, Duong FH, Hunziker L, Stuetvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. 2003. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. *Gastroenterology* 124:1465–1475.
- Bode JG, Ludwig S, Ehrhardt U, Erhardt A, Schaper F, Heinrich PC, Haussinger D. 2003. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. *FASEB J* 17:488–490.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 38:645–652.
- de Lucas S, Bartolome J, Carreno V. 2005. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. *J Infect Dis* 191:93–99.
- Dienstag JL, McHutchison JG. 2006. American Gastroenterological Association medical position statement on the management of hepatitis C. *Gastroenterology* 130:225–230.
- Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J Virol* 81:8211–8224.
- Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncalves FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol* 43:425–433.
- Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Loschenberger K, Steindl-Munda P. 2010. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. *Gastroenterology* 138:503–512 e501.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461:399–401.
- Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140:346–355.
- Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T,

- Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. 2009. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. *J Viral Hepat* 16:586–594.
- Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. 2009. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. *Cancer Sci* 100:2465–2468.
- Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouse K, Iwasaki Y, Ikeda M, Kato N, Yamamoto K. 2010. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-alpha in vitro. *Liver Int* 30:1324–1331.
- Joo M, Hahn YS, Kwon M, Sadikot RT, Blackwell TS, Christman JW. 2005. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. *J Virol* 79:7648–7657.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87:9524–9528.
- Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. 2010. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. *J Med Virol* 82:41–48.
- Lai MM, Ware CF. 2000. Hepatitis C virus core protein: Possible roles in viral pathogenesis. *Curr Top Microbiol Immunol* 242:117–134.
- Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, Holtzman MJ, Chung RT. 2006. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. *J Virol* 80:9226–9235.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. *Lancet* 358:958–965.
- McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. 2002. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 123:1061–1069.
- McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 361:580–593.
- Melen K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I. 2004. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. *J Med Virol* 73:536–547.
- Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, Kanai F, Imazeki F, Yokosuka O. 2009. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. *Scand J Gastroenterol* 44:872–877.
- Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H. 2009. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: A Japanese multi-center study. *J Gastroenterol* 44:952–963.
- Osna NA, White RL, Krutik VM, Wang T, Weinman SA, Donohue TM, Jr. 2008. Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress. *Gastroenterology* 134:2144–2152.
- Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. 2009. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. *J Viral Hepat* 16:578–585.
- Pearlman BL, Ehleben C, Saifee S. 2007. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. *Hepatology* 46:1688–1694.
- Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 128:636–641.
- Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, Zeuzem S. 2010. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. *J Hepatol* 52:832–838.
- Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology* 48:1753–1760.
- Strader DB, Wright T, Thomas DL, Seeff LB. 2004. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 39:1147–1171.
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 41:1100–1104.
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41:1105–1109.
- Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. *Gastroenterology* 139:120–129 e118.
- Waris G, Felmlee DJ, Negro F, Siddiqui A. 2007. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. *J Virol* 81:8122–8130.